Effect of pulmonary surfactant combined with NCPAP on serum ET-1 and CC16 in neonates with respiratory failure

doi:10.3877/cma.j.issn.1674-6902.2020.05.009

Abstract

Abstract:

Objective

To investigate the effect of pulmonary surfactant combined with NCPAP on ET-1 and CC16 in neonates with respiratory failure.

Methods

from January 2017 to November 2018, a total of 117 patients with neonatal respiratory failure were randomly divided into two groups: observation group 60 cases and control group 54 cases. Both groups received routine nursing and symptomatic treatment. The control group was treated with NCPAP to control the symptoms of respiratory failure. The observation group was treated with pulmonary surfactant on this basis. The two groups were treated for 3 consecutive days. The changes of PaO₂, PaCO₂ and SaO₂ levels before and after treatment were compared After treatment, the adverse reactions of the two groups were recorded and counted. The changes of serum ET-1 and CC16 before and after treatment were compared.

Results

there was no significant difference in PaO₂, PaCO₂ and SaO₂ between the two groups before and after the treatment. The above indexes of the two groups were significantly improved after the treatment, and the patients in the observation group were significantly improved compared with the patients in the control group, the results were statistically significant(P<0.05); the total effective rate of the observation group was 82.46%, the total effective rate of the control group was 64.91%, the effective rate of the observation group was significantly higher than that of the control group, the results were There was statistical significance; there was no significant difference in the incidence of adverse reactions between the two groups; there was no significant difference in the expression of serum ET-1 and CC16 between the two groups before the treatment; after the treatment, the expression of serum ET-1 and CC16 in the two groups were significantly reduced, and the observation group was significantly lower than the control group, the results were statistically significant.

Conclusion

pulmonary surfactant combined with NCPAP is more effective in the treatment of neonatal respiratory failure, and can effectively reduce the expression of serum ET-1 and CC16.

Key words: Pulmonary surfactant, Nasal continuous positive airway pressure, Neonatal respiratory failure, ET-1, CC16

Junlan Li, Xiaorong Zhang. Effect of pulmonary surfactant combined with NCPAP on serum ET-1 and CC16 in neonates with respiratory failure[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(05): 623-627.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.05.009

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I05/623

Figures/Tables 2

References 33

1	刘　莉，吕蓉蓉，陈光耀，等. 肺表面活性物质联合HFO对新生儿呼吸衰竭的疗效及对血清CK-MB、ET-1、Cys-C的影响[J]. 国际呼吸杂志，2018, 38(13): 996-1000.
2	沈金鑫. 无创高频通气在新生儿呼吸衰竭中的应用[J]. 国际儿科学杂志，2017, 44(12): 835-838.
3	Nikolopoulou M, Byraki A, Ahlberg J, et al. Oral appliance therapy versus nasal continuous positive airway pressure in obstructive sleep apnoea syndrome: a randomised, placebo-controlled trial on self-reported symptoms of common sleep disorders and sleep-related problems[J]. Journal of Oral Rehabilitation, 2017, 44(6): 452-460.
4	朱兴旺，闫　军，冉　琴，等. 无创高频振荡通气治疗新生儿呼吸窘迫综合征的初步研究[J]. 中华新生儿科杂志(中英文), 2017, 32(4): 291-294.
5	李　静，武瑞芳. 无创机械通气治疗阻塞性睡眠呼吸暂停低通气综合征的疗效及对患者血清炎性因子的影响[J]. 中国基层医药，2018, 25(20): 2638-2641.
6	王　华，母得志. 新生儿呼吸窘迫综合征的通气策略[J/CD]. 中华妇幼临床医学杂志(电子版), 2017, 13(1): 10-13.
7	周　海，郏　琴. 重度COPD稳定期患者血清CC16、SP-D、MSP与患者肺功能、病情严重程度的关系[J]. 临床肺科杂志，2019, 24(7): 1168-1171.
8	聂振清，陈晓燕. 机械通气联合不同肺表面活性物质在新生儿呼吸窘迫综合征中的价值[J]. 安徽医药，2019, 23(6): 1222-1225.
9	Sardesai Smeeta, Biniwale Manoj, Wertheimer Fiona, et al. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future[J]. Pediatr Res, 2017, 81(1-2): 240-248.
10	马加宝，陈　凯. 临床新生儿学[M]. 山东科学技术出版社，2002: 63-65.
11	Alapati D, Aghai ZH, Hossain MJ, et al. Lung Rest During Extracorporeal Membrane Oxygenation for Neonatal Respiratory Failure-Practice Variations and Outcomes[J]. Pediatric Critical Care Medicine, 2017, 18(7): 667-674.
12	Aldana-Aguirre JC, Pinto M, Featherstone RM, et al. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2017, 102(1): 17-23.
13	Zhu XW, Shi Y, Shi LP, et al. Non-invasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: Study protocol for a multi-center prospective randomized controlled trial[J]. Trials, 2018, 19(1): 319-321.
14	Liu J, Wang Q, Qian SY, et al. Nasal continuous positive airway pressure ventilation in children with community-acquired pneumonia under five years of age: a prospective, multi-center clinical study[J]. Chinese Journal of Pediatrics, 2017, 55(5): 329-333.
15	Fuloria Mamta, Aschner Judy L. Persistent pulmonary hypertension of the newborn[J]. Semin Fetal Neonatal Med, 2017, 22(4): 220-226.
16	Yuan-Zeng HE, Wen-Feng W, Department IM. Effect of sequential mechanical ventilation on cardiac function，endothelial injury and oxidative stress response in patients with cor pulmonale[J]. Journal of Hainan Medical University, 2017, 23(15): 2029-2035.
17	Raschetti Roberto, Centorrino Roberta, Letamendia Emmanuelle, et al. Estimation of early life endogenous surfactant pool and CPAP failure in preterm neonates with RDS[J]. Respir Res, 2019, 20(1): 75-78.
18	Thébaud Bernard, Goss Kara N, Laughon Matthew, et al. Bronchopulmonary dysplasia[J]. Nat Rev Dis Primers, 2019, 5(1): 78-81.
19	Carlo Dani, Mosca Fabio, Vento Giovanni, et al. Effects of surfactant treatment in late preterm infants with respiratory distress syndrome[J]. J Matern Fetal Neonatal Med, 2018, 31(10): 1259-1266.
20	Niemarkt HJ, Hütten MC, Kramer Boris W, et al. Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications[J]. Neonatology, 2017, 111(4): 408-414.
21	Suzuki Takuji, Trapnell Bruce C.Pulmonary Alveolar Proteinosis Syndrome[J]. Clin Chest Med, 2016, 37(3): 431-440.
22	Calkovska Andrea, Mokra Daniela, Calkovsky Vladimir, et al. Clinical considerations when treating neonatal aspiration syndromes[J]. Expert Rev Respir Med, 2019, 13(2): 193-203.
23	原　静，李书芳，李亚菲，等. 不同机械通气方式治疗新生儿呼吸衰竭的效果及对患儿CC16、KL-6水平的影响[J]. 河北医科大学学报，2019, 40(5): 551-555.
24	Tazawa Ryushi, Takahiro Ueda, Mitsuhiro Abe, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis[J]. N Engl J Med, 2019, 381(10): 923-932.
25	Kumar Anupam, Abdelmalak Basem, Inoue Yoshikazu, et al. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach[J]. Lancet Respir Med, 2018, 6(7): 554-565.
26	Woo Bae Chong, Kim Chae Young, Chung Sung Hoon, et al. History of Pulmonary Surfactant Replacement Therapy for Neonatal Respiratory Distress Syndrome in Korea[J]. J Korean Med Sci, 2019, 34(25): 175-177.
27	Ballard Philip L, Keller Roberta L, Truog William E, et al. Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment[J]. Pediatr Res, 2019, 85(3): 305-311.
28	Mikolka Pavol, Kopincova Jana, Kosutova Petra, et al. Anti-IL-8 antibody potentiates the effect of exogenous surfactant in respiratory failure caused by meconium aspiration[J]. Exp Lung Res, 2018, 44(1): 40-50.
29	韩宜均，马文强. 呼吸机鼻塞式持续正压通气联合猪肺磷脂注射液对呼吸窘迫综合征新生儿动脉血气指标及症状改善的影响[J]. 新疆医学，2018, 48(6): 615-617.
30	张纪伟. 肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效分析[J]. 临床医学，2017, 37(3): 113-114.
31	Trapnell Bruce C, Nakata Koh, Bonella Francesco, et al. Pulmonary alveolar proteinosis[J]. Nat Rev Dis Primers, 2019, 5(1): 16-19.
32	Roberts Calum T, Owen Louise S, Manley Brett J, et al. Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants[J]. N Engl J Med, 2016, 375(12): 1142-1151.
33	Vincent Rigo, Lefebvre Caroline, Broux Isabelle. Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis[J]. Eur J Pediatr, 2016, 175(12): 1933-1942.

组　别	例数	ET-1(ng/L)				CC16(ng/L)
组　别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	60	77.81±3.06	48.17±1.67	65.860	0.000	0.55±0.62	0.18±0.17	4.458	0.000
对照组	54	77.03±1.65	62.62±1.65	45.379	0.000	0.53±1.05	0.31±0.23	3.372	0.001
t值		1.667	46.391			0.125	3.521
P值		0.098	0.000			0.901	0.001

组　别	例数	ET-1(ng/L)				CC16(ng/L)
组　别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	60	77.81±3.06	48.17±1.67	65.860	0.000	0.55±0.62	0.18±0.17	4.458	0.000
对照组	54	77.03±1.65	62.62±1.65	45.379	0.000	0.53±1.05	0.31±0.23	3.372	0.001
t值		1.667	46.391			0.125	3.521
P值		0.098	0.000			0.901	0.001

组　别	例数	PaO₂(mmHg)		PaCO₂(mmHg)		SaO₂(%)
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	60	46.81±1.11	82.17±0.67^a	60.15±2.62	38.08±1.77^a	0.72±0.06	0.91±0.08^a
对照组	54	46.93±1.32	64.14±0.91^a	60.27±1.05	45.01±1.23^a	0.71±0.45	0.84±0.03^a
t值		0.527	121.260	0.320	24.017	0.171	6.056
P值		0.599	0.000	0.750	0.000	0.865	0.000

组　别	例数	PaO₂(mmHg)		PaCO₂(mmHg)		SaO₂(%)
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	60	46.81±1.11	82.17±0.67^a	60.15±2.62	38.08±1.77^a	0.72±0.06	0.91±0.08^a
对照组	54	46.93±1.32	64.14±0.91^a	60.27±1.05	45.01±1.23^a	0.71±0.45	0.84±0.03^a
t值		0.527	121.260	0.320	24.017	0.171	6.056
P值		0.599	0.000	0.750	0.000	0.865	0.000

[1]	Dingyi Wang, Yong Yang, Runrun Yang, Yupin Li, Yunyou Duan. Application of lung ultrasound in evaluating therapeutic effects of pulmonary surfactants for neonatal respiratory distress syndrome [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2019, 16(10): 778-784.
[2]	Yan Wang, Fengjun Guo, Wenhui Zha, Chang Liu, Yaping Luan, Fuju Wu. Clinical application values of pulmonary artery blood flow indexes and pulmonary surfactant protein level for perinatal lung maturity when pregnant women complicated with severe preeclampsia and gestational diabetes mellitus [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(06): 692-698.
[3]	Jingfang Zhai, Jiebin Wu, Xiao Liu, bao Jin, Yanbo Wang, Yang Chen, Yun Wang, Guangling Zhou, Bin Zhou. Application of noninvasive high frequency oscillation ventilation in initial respiratory support of very low birth weight premature infants with respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(05): 598-605.
[4]	Fudong Wang, Mingfeng Fu, Minhua Chen, Mingfu Wu, Xiangfang Song, Li Zhang, Feng Liu, Lijun Jiang. Clinical research of different pulmonary surfactant administration techniques on premature infants with respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(03): 299-308.
[5]	Li Liu, Jun Tang. Current status of prevention and treatment of neonatal meconium aspiration syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(03): 249-256.
[6]	Bao Jin, Xiangyu Gao, Bo Yang, Di Huang, Yi Ren. Clinical research of caffeine citrate combined with heated humidified high-flow nasal cannula for prevention of extubation failure in premature infants with respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(06): 695-702.
[7]	Jingfang Zhai, Jiebin Wu, Bao Jin, Xiao Liu, Yanbo Wang, Guangling Zhou, Xiaoyu Song, Ke Wang, Bin Zhou, Kai Wang. Comparison of heated humidified high flow nasal cannula and nasal continuous positive airway pressure in initial respiratory support of mild neonatal respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(06): 632-638.
[8]	Wenxing Li, Jun Tang, Chao Chen, Xia Qiu, Yan Yue, Yan Zeng, Yi Qu, Dezhi Mu. Comparison of heated humidified high-flow nasal cannula and nasal continuous positive airway pressure in preventing extubation failure in preterm infants: a Meta-analysis [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(02): 171-179.
[9]	Keren Luo, Jun Tang. Research advances in the composition and function of pulmonary surfactant [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(02): 137-142.
[10]	Shuqiang Gao, Rong Ju, Sheng Yang, Yiting Du, Wenbin Dong. Pulmonary ultrasonic manifestations in neonatal respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(01): 68-72.
[11]	Wei Tan, Langhuan Lei, Liping Yao, Qiufen Wei, Yan Li. Comparison of curative effects of using pulmonary surfactant at different time in treatment of premature infants with respiratory distress syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2017, 13(04): 455-460.
[12]	Shijun Wen, Yunhuan Zhang, Chengyuan Li. Value of PS combined with bi-level continuous positive airway pressure in the treatment of preterm infants with NRDS [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(06): 755-759.
[13]	Na Liu, Ranran Zhao. Effects of acetylcysteine adjuvant therapy on AECOPD and its influence on airway remodeling, oxidative stress status and levels of serum SP-A, SP-D and CC16 [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 174-178.
[14]	Zhiying Yin, Hao Wang, Yongqiang Li, Yujuan Wang, Shixia Ma, Siqing Ma. Expression and effect of pulmonary surfactant protein-D in the occurrence and development of high altitude pulmonary edema [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(03): 235-239.
[15]	qi Tian. Change of serum Clara cell secretory protein 16, tumor necrosis factor-α, interleukin-6 and pulmonary surfactant protein D in children with severe pneumonia [J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(03): 192-196.

Please choose a citation manager

Content to export